Dina Kao on a trial of lyophilised sterile faecal filtrate versus lyophilised conventional donor stool for recurrent Clostridiodes difficile infection
15:55
Premysl Bercik on a double-blind crossover trial of gluten and wheat in IBS
16:21
Julia Mayerle on the validation of plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma
26:52
Salvatore Piano on the global epidemiology of acute kidney injury in hospitalised patients with decompensated cirrhosis
19:05
John Chia on the ASCOLT trial of adjuvant aspirin for colorectal cancer
13:29
Hannes Hagström on screening for advanced liver fibrosis alongside retina scanning in people with type 2 diabetes
21:23
Cathy Lu on intestinal ultrasound for assessing and monitoring Crohn's disease small bowel strictures
11:15
Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis
14:42
Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease
34:15
Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer
18:23
Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy
25:05
Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS
23:16
Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease
19:55
Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa
20:54
Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake
16:39
Louise Dye on the role of expectancy and gluten in non-coeliac gluten sensitivity
23:19
Tzu-Chan Hong on the primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region
14:40
Sarah Moen on metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after colectomy
14:45
Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease
16:19
Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction
16:31
Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis
14:29
Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease
17:41
Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis
12:48
Adelina Artenie on the incidence of HIV and HCV in people who inject drugs
17:15
Johan Burisch on the costs of inflammatory bowel disease in high-income settings
20:00